Johnson & Johnson completes acquisition deal with Aragon Pharmaceuticals.
Advertisement
On Aug. 19 2013, Johnson & Johnson completed its acquisition of Aragon Pharmaceuticals, a pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. Development of compounds from Aragon’s androgen receptor antagonist program, including its androgen receptor signaling inhibitor, ARN-509, will be managed by Janssen Research & Development.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.